Amiloride is neuroprotective in an MPTP model of Parkinson's disease

Neurobiology of Disease

Volumn 31, Issue 3, 2008, Pages 334-341

  Arias, Robert L ^a   Sung, Mei Li A ^a   Vasylyev, Dmytro ^a   Zhang, Mei Yi ^a   Albinson, Kristin ^a   Kubek, Katie ^a   Kagan, Natasha ^a   Beyer, Chad ^a   Lin, Qian ^a   Dwyer, Jason M ^a   Zaleska, Margaret M ^a   Bowlby, Mark R ^a   Dunlop, John ^a   Monaghan, Michael ^a  

^a PFIZER INC   (United States)

Author keywords

Amiloride; ASIC; Dopamine transporter; MPTP; Parkinson's disease; Psalmotoxin; Substantia nigra; Tyrosine hydroxylase

Indexed keywords

1,2,3,6 TETRAHYDRO 1 METHYL 4 PHENYLPYRIDINE; AMILORIDE; DOPAMINE; DOPAMINE TRANSPORTER; PSALMOTOXIN; RADIOLIGAND; TYROSINE 3 MONOOXYGENASE; UNCLASSIFIED DRUG; VENOM;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BRAIN DEGENERATION; BRAIN ISCHEMIA; CONTROLLED STUDY; DOPAMINERGIC NERVE CELL; IMMUNOHISTOCHEMISTRY; LACTIC ACIDOSIS; MALE; MOUSE; NERVE CELL; NEUROPROTECTION; NONHUMAN; PARKINSON DISEASE; PATCH CLAMP; PRIORITY JOURNAL; STRIATE CORTEX; SUBSTANTIA NIGRA;

1-METHYL-4-PHENYL-1,2,3,6-TETRAHYDROPYRIDINE; ACIDOSIS, LACTIC; AMILORIDE; ANIMALS; ANTIPARKINSON AGENTS; BINDING, COMPETITIVE; DISEASE MODELS, ANIMAL; DOPAMINE; DOPAMINE PLASMA MEMBRANE TRANSPORT PROTEINS; MALE; MICE; MICE, INBRED C57BL; NERVE TISSUE PROTEINS; NEURONS; NEUROPROTECTIVE AGENTS; PARKINSONIAN DISORDERS; RADIOLIGAND ASSAY; SODIUM CHANNEL BLOCKERS; SODIUM CHANNELS; SPIDER VENOMS; SUBSTANTIA NIGRA; TYROSINE 3-MONOOXYGENASE;

EID: 49349115297     PISSN: 09699961     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.nbd.2008.05.008     Document Type: Article

References (58)

1. Abeliovich A., and Beal M. Parkinsonism genes: culprits and clues. J. Neurochem. 99 (2006) 1062-1072
2. Alfinito P., Wang S., Manzino L., Rijhsinghani S., Zeevalk G., and Sonsalla P. Adenosinergic protection of dopaminergic and GABAergic neurons against mitochondrial inhibition through receptors located in the substantia nigra and striatum, respectively. J. Neurosci. 34 (2003) 10982-10987
3. Ascherio A., and Zhang S. Prospective study of caffeine consumption and risk of Parkinson's disease in men and women. Ann. Neurol. 50 (2001) 56-63
4. Bender A., Krishnan K., Morris C., Taylor G., Reeve A., Perry R., Jaros E., Hersheson J., Betts J., Klopstock T., Taylor R., and Turnbull D. High levels of mitochondrial DNA deletions in substantia nigra neurons in aging and Parkinson's disease. Nat. Genet. 38 (2006) 515-517
5. Bove J., Prou D., Perier C., and Przedborski S. Toxin-induced models of Parkinson's disease. NeuroRx 2 (2005) 484-494
6. Bowen B.C., Block R.E., Sanchez-Ramos J., Pattany P.M., Lampman D.A., Murdoch J.B., and Quencer R.M. Proton MR spectroscopy of the brain in 14 patients with Parkinson disease. Am. J. Neuroradiol. 16 (1995) 61-68
7. Braak H., Tredici K., Rub U., Vos Rd, Steur E., and Braak E. Staging of brain pathology related to sporadic Parkinson's disease. Neurobiol. Aging 24 (2003) 197-211
8. Brouillet E., and Beal M.F. NMDA antagonists partially protect against MPTP induced neurotoxicity in mice. NeuroReport 4 (1993) 387-390
9. Chen J. Neuroprotection by caffeine and A2A adenosine receptor inactivation in a model of Parkinson's disease. J. Neurosci. 21 (2001) RC143
10. Dauer W., and Przedborski S. Parkinson's disease: mechanisms and models. Neuron 39 (2003) 889-909
11. Escoubas P., Bernard C., Lambeau G., Lazdunski M., and Darbon H. Recombinant production and solution structure of PcTx1, the specific peptide inhibitor of ASIC1a proton-gated cation channels. Protein Sci. 12 (2003) 1332-1343
12. Fahn S. Description of Parkinson's disease as a clinical syndrome. Ann. N. Y. Acad. Sci. 991 (2003) 1-14
13. Ferger B., Leng A., Mura A., Hengerer B., and Feldon J. Genetic ablation of tumor necrosis factor-alpha (TNF-alpha) and pharmacological inhibition of TNF-synthesis attenuates MPTP toxicity in mouse striatum. J. Neurochem. 89 (2004) 822-833
14. Franklin K.B.J., and Paxinos G. The Mouse Brain in Stereotaxic Coordinates. 3rd ed. (2008), Academic Press, New York
15. Friese M.A., Craner M.J., Etzensperger R., Vergo S., Wemmie J.A., Welsh M.J., Vincent A., and Fugger L. Acid-sensing ion channel-1 contributes to axonal degeneration in autoimmune inflammation of the central nervous system. Nat. Med. 13 (2007) 1483-1489
16. Garritsen A., Ijzerman A., Beukers M., Cragoe E., and Soudijn W. Interaction of amiloride and its analogues with adenosine A1 receptors in calf brain. Biochem. Pharmacol. 40 (1990) 827-834
17. Gupta A.K., Zygun D.A., Johnston A.J., Steiner L.A., Al-Rawi P.G., Chatfield D., Shepherd E., Kirkpatrick P.J., and Menon D.K. Extracellular brain pH and outcome following severe traumatic brain injury. J. Neurotrauma 21 (2004) 678-684
18. Haddad J., and Land S. Amiloride blockades lipopolysaccharides-induced proinflammatory cytokine biosynthesis in an IκB-α/NF-κB-dependent mechanism: evidence for the amplification of an anti-inflammatory pathway in the alveolar epithelium. Am. J. Respir. Cell Mol. Biol. 26 (2002) 114-126
19. Horisberger J.-D. Amiloride-sensitive Na+ channels. Curr. Opin. Cell Biol. 10 (1998)
20. Immke D.C., and McCleskey E.W. Lactate enhances the acid-sensing Na+ channel on ischemia-sensing neurons. Nat. Neurosci. 4 (2001)
21. Inamura K., Smith M.-L., Olsson Y., and Siesjo B.K. Pathogenesis of substantia nigra lesions following hyperglycemic ischemia: changes in energy metabolites, cerebral blood flow, and morphology of pars reticulata in a rat model of ischemia. J. Cereb. Blood Flow Metab. 8 (1988) 375-384
22. Jenner P. Oxidative stress in Parkinson's disease. Ann. Neurol. 3 (2003) 26-38
23. Joch M., Ase A.R., Chen C.X.-Q., MacDonald P.A., Kontogiannea M., Corera A.T., Brice A., Seguela P., and Fon E.A. Parkin-mediated monoubiquitination of the PDZ protein PICK1 regulates the activity of acid-sensing ion channels. Mol. Biol. Cell 18 (2007) 3105-3118
24. Kellenberger S., and Schild L. Epithelial sodium channel/degenerin family of ion channels: a variety of functions for a shared structure. Physiol. Rev. 82 (2002) 735-767
25. Kitada T., Asakawa S., Hattori N., Matsumine H., Yamamura Y., Minoshima S., Yokochi M., Mizuno Y., and Shimizu N. Mutations in the parkin gene cause autosomal recessive juvenile parkinsonism. Nature 392 (1998) 605-608
26. Kleyman T.R., and Cragoe E.J. Amiloride and its analogs as tools in the study of ion transport. J. Membr. Biol. 105 (1988) 1-21
27. 1H MRS identifies lactate rise in the striatum of MPTP-treated C57BL/6 mice. Eur. J. Pharmacol. 23 (2006) 1077-1081
28. Krishtal O. The ASICs: signaling molecules? Modulators?. TINS 26 (2003) 477-483
29. Kristian T. Metabolic stages, mitochondria and calcium in hypoxic/ischemic brain damage. Cell Calcium 36 (2004) 221-233
30. Lang A., and Obesso J. Challenges in Parkinson's disease: restoration of the nigrostriatal dopamine system is not enough. Lancet Neurol. 3 (2004) 309-316
31. Lee V.-Y., and Trojanowski J. Mechanisms of Parkinson's disease linked to pathological α-synuclein: new targets for drug discovery. Neuron 52 (2006) 33-38
32. Mandemakers W., Marais V., and Strooper B. A cell biological perspective on mitochondrial dysfunction in Parkinson disease and other neurodegenerative diseases. J. Cell Sci. 120 (2007) 1707-1716
33. Martone R., Monaghan M., and Pangalos M. Parkinson's disease as a disorder of the aging. Drug Discov. Today: Ther. Strateg. 2 (2005) 299-305
34. McCoy M., Martinez T., Ruhn K., Szymkowski D., Smith C., Botterman B., Tansey K., and Tansey M. Blocking soluble tumor necrosis factor signaling with dominant-negative tumor necrosis factor inhibitor attenuates loss of dopaminergic neurons in models of Parkinson's disease. J. Neurosci. 26 (2006) 9365-9375
35. Moore D., West A., Dawson V., and Dawson T. Molecular pathophysiology of Parkinson's disease. Ann. Rev. Neurosci. 28 (2005) 57-87
36. Murray T.K., Whalley K., Robinson C.S., Ward M.A., Hicks C.A., Lodge D., Vandergriff J.L., Baumbarger P., Siuda E., Gates M., Ogden A.M., Skolnick P., Zimmerman D.M., Nisenbaum E.S., Bleakman D., and O'Neill M.J. LY503430, a novel α-amino-3-hydroxy-5-methylisoxazole-4-propionic acid receptor potentiator with functional, neuroprotective and neurotrophic effects in rodent models of Parkinson's disease. JPET 306 (2003) 752-762
37. h channels contribute to the different functional properties of identified dopaminergic subpopulations in the midbrain. J. Neurosci. 22 (2002) 1290-1302
38. Pidoplichko V.I., and Dani J.A. Acid-sensitive ionic channels in midbrain dopamine neurons are sensitive to ammonium, which may contribute to hyperammonemia damage. PNAS 103 (2006) 11376-11380
39. Pignataro G., Simon R.P., and Xiong Z.-G. Prolonged activation of ASIC1a and the time window for neuroprotection in cerebral ischaemia. Brain 130 (2007) 151-158
40. Ross G. Association of coffee and caffeine intake with the risk of Parkinson disease. JAMA 283 (2000) 2674-2679
41. Schwarzschild M., Agnati L., Fuxe K., Chen J., and Morelli M. Targeting adenosine A2A receptors in Parkinson's disease. Trends Neurosci. 29 (2006) 647-654
42. Shen J., and Cookson M. Mitochondria and dopamine: new insights into recessive parkinsonism. Neuron 43 (2004) 301-304
43. Siesjo B.K., Katsura K.-i., and Kristian T. Acidosis-related damage. Adv. Neurol. 71 (1996) 209-236
44. Smith M.-L., Kalimo H., Warner D., and Siesjo B. Glucose treatment preceding forebrain ischemia causes substantia nigra damage. J. Cereb. Blood Flow Metab. 7 suppl 1 (1987) S76
45. Sririm K., Matheson J., Benkovic S., Miller D., Luster M., and O'Callaghan J. Deficiency of TNF receptors suppresses microglial activation and alters the susceptibility of brain regions to MPTP-induced neurotoxicity: role of TNFα. FASEB J. 20 (2006) 670-682
46. Teismann P., and Ferger B. Inhibition of the cyclooxygenase isoenzymes COX-1 and COX-2 provide neuroprotection in the MPTP-mouse model of Parkinson's disease. Synapse 39 (2001) 167-174
47. i, cerebral blood flow, and NADH fluorescence during severe incomplete global ischemia in rabbits. Stroke 24 (1993) 435-443
48. Veselovsky N.S., Engert F., and Lux H.D. Fast local superfusion technique. Pflugers Arch. 432 (1996) 351-354
49. +-gated cation channels: neuronal acid sensors in the NaC/DEG family of ion channels. Curr. Opin. Neurobiol. 8 (1998) 418-424
50. Wemmie J.A., Askwith C.C., Lamani E., Cassell M.D., Freeman Jr. J.H., and Welsh M.J. Acid-sensing ion channel 1 is localized in brain regions with high synaptic density and contributes to fear conditioning. J. Neurosci. 23 (2003) 5496-5502
51. Wemmie J.A., Price M.P., and Welsh M.J. Acid-sensing ion channels: advances, questions and therapeutic opportunities. TINS 29 (2006) 578-586
52. Wu D., Jackson-Lewis V., Vila M., Tieu K., Teismann P., Vadseth C., Choi D., Ischiropoulos H., and Przedborski S. Blockade of microglial activation is neuroprotective in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine mouse model of Parkinson disease. J. Neurosci. 22 (2002) 1763-1771
53. Xiong Z.-G., Zhu X.-M., Chu X.-P., Minami M., Hey J., Wei W.-L., MacDonald J.F., Wemmie J.A., Price M.P., Welsh M.J., and Simon R.P. Neuroprotection in ischemia: blocking calcium-permeable acid-sensing ion channels. Cell 118 (2004) 687-698
54. 2+-permeable acid-sensing ion channels and ischemic brain injury. J. Membr. Biol. 209 (2006) 59-68
55. Xu K., Xu Y., Chen J., and Schwarzschild M. Caffeine's neuroprotection against 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine toxicity shows no tolerance to chronic caffeine administration in mice. Neurosci. Lett. 322 (2002) 13-16
56. Yao H., and Haddad G.G. Calcium and pH homeostasis in neurons during hypoxia and ischemia. Cell Calcium 36 (2004) 247-255
57. Yermolaieva O., Leonard A.S., Schnizler M.K., Abboud F.M., and Welsh M.J. Extracellular acidosis increases neuronal cell calcium by activating acid-sensing ion channel 1a. PNAS 101 (2004) 6752-6757
58. Zygun D.A., Steiner L.A., Johnston A.J., Hutchinson P.J., Al-Rawi P.G., Chatfield D., Kirkpatrick P.J., Menon D.K., and Gupta A.K. Hyperglycemia and brain tissue pH after traumatic brain injury. Neurosurgery 55 (2004) 877-882